Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
Jan Lewis Brandes(Merck & Co., Inc., Rahway, NJ, USA (United States)), David Kudrow(California Medical Clinic for Headache), Joel Raskin(Eli Lilly (United Kingdom)), John H. Krege(Eli Lilly (United States)), Eric Pearlman(University of California, San Francisco), Michael Case(Eli Lilly (United States)), Rashna Khanna(Eli Lilly (United States)), Raghavendra Vasudeva(Eli Lilly (United States)), Suzanne Klise(Eli Lilly (United States))
Cited by 99
Related Papers
Generation and reproductive phenotypes of mice lacking estrogen receptor β
|Proceedings of the National Academy of Sciences|1998|1.7k
Elevated blood pressures in mice lacking endothelial nitric oxide synthase
|Proceedings of the National Academy of Sciences|1996|903
Genetic control of blood pressure and the angiotensinogen locus.
|Proceedings of the National Academy of Sciences|1995|642